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摘  要 







Twist2/SKOV3，采用 MTT 法、流式细胞仪、划痕实验等方法检测 Twist2 对细胞
生长及迁移功能的影响，采用基因芯片技术对 Twist2 调控的下游基因进行系统
地分析，并结合 Real-time PCR 和 Western Blot 加以验证。 
结果  Twist2 在正常卵巢组织中几乎不表达，在卵巢癌组织中表达明显升高，总






各组无显著性差异，表明 Twist2 的表达与肿瘤组织类型无关。Twist2 过表达时
细胞形态也发生改变，细胞由原先的不规则多边形，聚集成团，铺石状排列，转
变为梭形，成纤维样，且明显促进了细胞迁移和侵袭的能力，但是对细胞增殖无
明显影响，提示 Twist2 可能参与了卵巢癌的 EMT。Twist2 的过表达使卵巢癌
SKOV3 细胞的 E-cadherin、APC 表达下调，N-cadherin、β-catenin、Claudin-1 和
Claudin-3 表达上升，同时，细胞核内 β-catenin 表达增加，提示 Twist2 的过表达
使 E-cadherin 的表达下调，从而使得 E-cadherin/β-catenin 复合体中的 β-catenin
游离出来，且 APC 的下调进一步使 β-catenin 降解减少，游离的 β-catenin 增加，
并在胞浆积聚而进入细胞核增多，激活经典的 Wnt/β-catenin/Tcf 信号通路，启动















SKOV3 细胞的 IL-6、P-STAT3（Tyr705）、MMP2、MMP9 表达上升，推测 Twist2
的过表达可使 IL-6 的表达上调，激活 STAT3，而活化的 STAT3 可借助核转运蛋









































Objective:  This project aims to investigate the significance of a b-HLH 
transcription factor Twist2 in human ovarian cancer and the underlying mechanism of 
Twist2 which promotes ovarian cancer progression. It also endeavors to screen the 
downstream genes of Twist2 which involved in the invasive and metastatic process of 
cancer cells, to present data for relevant downstream signals of Twist2, and further to 
provide a novel target for clinical translational therapy of ovarian cancer. 
Method:  Immunohistochemistry was used to detect the expression of the Twist2 
protein on microarray tissue of human ovarian cancer with scoring procedure 
according to staining intensity and the extent of straining. The Twist2 gene was stably 
transfected into human ovarian cancer line SKOV3 by cloning and lipofectamine 
transfection technique. To determine whether Twist2 is a crucial mediator of cancer , 
various methods are applied in Twist2 over-expression cell line compared with 
parental cell, including MTT assay, flow cytometry(FCM) and scratch test. Gene 
microarray technology was adopted to provide systematic analysis of downstream 
gene of Twist2. The EMT-related results were verified with Real-time PCR and 
Western Blot. 
Results:  Twist2 was significantly increased in malignant tumor (70.24%, 59 in 84 
cases) compared with normal ovarian tissue. The expression of Twist2 was  
increased accompanied with the FIGO stage, exemplified as following: 22.73% at 
stage Ⅰ(10 in 44 cases), while 53.85% at stage Ⅳ (7 in 13 cases). This indicated that 
increasing of Twist2 was related with ovarian cancer invasion and metastasis. 
According to histological type classification, strong expression of Twist2 was found 
in 19 of 69 serous carcinomas (27.54%), 1 of 8 mucinous carcinomas (12.5%), none 
of 4 endometriod carcinomas (0%), and 2 of 5 Clear cell carcinomas (40%). However 
there is no correlation between Twist2 expression and the tumor histological type. 















apposed to carcinoma islands, was transformed into fibroblast-like shape when Twist2 
over-expression, accompanied with increased motility and invasiveness whereby no 
change in cell proliferation ability. This indicated that Twist2 may be involved in 
EMT of ovarian cancer. The Twist2/SKOV3 cells showed featuring cellular and 
molecular changes that include: downregulation of E-cadherin, APC; upregulation of 
N-cadherin, β-catenin (adjoint in cell nucleus), Claudin-1 and Claudin-3, suggesting 
that Twist2 promote β-catenin release from E-cadherin/β-catenin through inhibition of 
E-cadherin. Therefore, due to downregulation of APC, β-catenin degradation was 
repressed, Wnt/β-catenin/Tcf pathway was then activated by nuclear β-catenin 
accumulation, thus evoked transcription of downstream target genes such as 
Claudin-1 and Claudin-3. Furthermore, Twist2 improved the expression level of IL-6, 
P-STAT3（Tyr705）, MMP2 and MMP9 in SKOV3, revealing that increased expression 
of Twist2 up-regulate IL-6 and activated STAT3. The activated STAT3 could get into 
nucleus through nuclear transport protein, and associated with specific DNA 
sequences to drive transcription of target genes MMP2 and MMP9.  
Conclusion： Twist2 protein is significantly increased in ovarian cancer tissues and 
the high level of Twist2 was correlated with FIGO stage, which is likely to be used as 
an indication of high grade of malignancy and poor prognosis in clinical ovarian 
cancer. Twist2 may be involved in two pathways lead to EMT of ovarian cancer: 
Twist2 may activate Wnt/β-catenin/Tcf pathway through inhibition of E-cadherin and 
activate IL-6/STAT3 pathway owe to the upregulation of IL-6, which will enhance the 
invasive and metastatic potential of ovarian cancer cells by increasing the expression 
of Claudin-1,MMP-2 and MMP-9.  
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第一章  前 言 
1 
第一章  前 言 
卵巢癌是女性生殖器官常见的肿瘤之一，发病率仅次于子宫颈癌和子宫体癌
而列居第三位，但致死率却占各类妇科肿瘤的首位。因卵巢癌临床起病隐匿，早
期无症状，75%妇女发现时已发展到临床 III 或 IV 期，多扩散转移，其 5 年生
存率低于 20%，对妇女生命造成严重威胁[1]。除少量来源于输卵管外，已知超过
90%的卵巢癌发生于卵巢表面上皮(OSE)。OSE 属初级上皮，是一类低分化的细
胞，既可表达上皮性标志物如 E-cadherin、keratins，又可表达间质标志物 vimentin, 
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